A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Obeticholic Acid In Subjects With Nonalcoholic Steatohepatitis
Email for information
Research Start Date
The primary objective of this study is to evaluate the effect of OCA compared to placebo on histological improvement in nonalcoholic steatohepatitis (NASH) by assessing the following primary endpoints using NASH Clinical Research Network (CRN) scoring criteria: Improvement in fibrosis by at least 1 stage with no worsening of NASH, or Resolution of NASH with no worsening fibrosis
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.